JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...
https://www.thehindubusinessline.com/markets/aurobindos-subsidiary-secures-approval-for-budesonide-inhalation-suspension/article67589939.ece Copy Aurobindo Pharma ...
Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Budesonide Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Sales of Budesonide increased ...
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...
Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic rhinosinusitis with nasal polyps when compared with placebo, according to study results. In a double ...
Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children from 12 months old to 8 years. Aurbodino ...
Research and Markets: Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback